Evidence map›Paper›PMID 41032091›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Oroxylin A exerts antiproliferative effects through downregulation of E6 and E7 oncogenes in cervical cancer HeLa cells.

Shan Hu, Yongting Lu, Pratibha Pandey, Md Ali Mujtaba, Shivam Pandey, Sorabh Lakhanpal, Meenakshi Verma, Fahad Khan

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shan HuDepartment of Anesthesiology, The Taiyun Hospital of Peking University First Hospital/Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, 030000, China.
Yongting LuDepartment of Gynaecology and Obstetrics, Xi'an No.3 Hospital, Xi'an, 710000, China. lu_yongting@sina.com.
Pratibha PandeyUniversity Centre for Research and Development, Chandigarh University, Gharuan, Mohali, Punjab, 140413, India.
Md Ali MujtabaCenter for Health Research, Northern Border University, Arar, 73213, Saudi Arabia.
Shivam PandeySchool of Applied and Life Sciences, Uttaranchal University, Dehradun, India.
Sorabh LakhanpalSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Meenakshi VermaUniversity Centre for Research and Development, Chandigarh University, Gharuan, Mohali, Punjab, 140413, India.
Fahad KhanCenter for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, 602105, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous plant compounds have shown promising antitumor potential against cervical cancer. Plant-based compounds offer abundantly available, easy, and inexpensive methods of treatment over genome-editing technologies (immunotherapeutics). Many flavonoids directly abrogated HPV-E6/E7 activity with a concomitant apoptotic conclusion. Cervical cancer initiation and progression are entirely dependent on the oncogenes E6 and E7 (constitutively expressed) leading to tumorigenesis. Therefore, the manipulation of these oncogenes is the most prominent form of cervical cancer therapeutics. To further explore the mechanism underlying apoptosis induction, ROS generation, apoptosis-related gene expression (Bcl-2, caspases-3, caspases-8, and caspases-9), viral oncogenes (E6/E7), and tumor suppressor proteins (p53/pRb) were evaluated using MTT, cell cycle arrest, Hoechst, docking, and RT-PCR analysis. This study showed that oroxylin A (OrA) effectively inhibited HeLa cell proliferation at the respective doses. This study suggests that OrA inhibits E6/E7 mRNAs, leading to the upregulation of p53/pRb (tumor suppressor genes) in HeLa cells. Moreover, OrA induced p53-mediated apoptosis induction, activating the transcription of various proapoptotic genes, including Bcl-2 and Bax. Alternatively, p53 triggers apoptosis by promoting the caspase activation. In conclusion, OrA targeting E6/E7 was highly effective in inhibiting cancer cell proliferation via the upregulation of suppressor genes in cervical cancer.

Indexed as

FlavonoidsOncogene Proteins, ViralPapillomavirus E7 ProteinsRepressor ProteinsUterine Cervical NeoplasmsApoptosisCell ProliferationDown-RegulationFemaleGene Expression Regulation, NeoplasticHeLa CellsHumansReactive Oxygen Species5,7-dihydroxy-6-methoxy-2-phenylchromen-4-oneE6 protein, Human papillomavirus type 16FlavonoidsOncogene Proteins, ViralPapillomavirus E7 ProteinsReactive Oxygen SpeciesRepressor ProteinsAnticancerApoptosisCervical cancerNatural productOroxylin A

Identifiers

PMID41032091

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.